Koch David G, Fallon Michael B
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of South Carolina, 25 Courtenay Drive ART 7100A, MSC 290, Charleston, SC 29425, USA.
Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, The University of Texas Medical School at Houston, 6431 Fannin Street, MSB 4234, Houston, TX 77030, USA.
Clin Liver Dis. 2014 May;18(2):407-20. doi: 10.1016/j.cld.2014.01.003. Epub 2014 Feb 25.
The hepatopulmonary syndrome (HPS) is a pulmonary complication of cirrhosis and/or portal hypertension whereby patients develop hypoxemia as a result of alterations in pulmonary microvascular tone and architecture. HPS occurs in up to 30% of patients with cirrhosis. Although the degree of hypoxemia does not reliably correlate with the severity of liver disease, patients with HPS have a higher mortality than do patients with cirrhosis without the disorder. There has been progress into defining the mechanisms that lead to hypoxemia in HPS, but to date there are no therapeutic options for HPS aside from liver transplantation.
肝肺综合征（HPS）是肝硬化和/或门静脉高压的一种肺部并发症，患者由于肺微血管张力和结构改变而出现低氧血症。高达30%的肝硬化患者会发生HPS。虽然低氧血症的程度与肝病严重程度并无可靠关联，但HPS患者的死亡率高于无此病症的肝硬化患者。在确定导致HPS低氧血症的机制方面已有进展，但迄今为止，除肝移植外，尚无针对HPS的治疗选择。
